Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets
- 15 December 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Neuropathologica
- Vol. 131 (6), 903-910
- https://doi.org/10.1007/s00401-015-1519-8
Abstract
With the number of prognostic and predictive genetic markers in neuro-oncology steadily growing, the need for comprehensive molecular analysis of neuropathology samples has vastly increased. We therefore developed a customized enrichment/hybrid-capture-based next-generation sequencing (NGS) gene panel comprising the entire coding and selected intronic and promoter regions of 130 genes recurrently altered in brain tumors, allowing for the detection of single nucleotide variations, fusions, and copy number aberrations. Optimization of probe design, library generation and sequencing conditions on 150 samples resulted in a 5-workday routine workflow from the formalin-fixed paraffin-embedded sample to neuropathological report. This protocol was applied to 79 retrospective cases with established molecular aberrations for validation and 71 prospective cases for discovery of potential therapeutic targets. Concordance of NGS compared to established, single biomarker methods was 98.0 %, with discrepancies resulting from one case where a TERT promoter mutation was not called by NGS and three ATRX mutations not being detected by Sanger sequencing. Importantly, in samples with low tumor cell content, NGS was able to identify mutant alleles that were not detectable by traditional methods. Information derived from NGS data identified potential targets for experimental therapy in 37/47 (79 %) glioblastomas, 9/10 (90 %) pilocytic astrocytomas, and 5/14 (36 %) medulloblastomas in the prospective target discovery cohort. In conclusion, we present the settings for high-throughput, adaptive next-generation sequencing in routine neuropathology diagnostics. Such an approach will likely become highly valuable in the near future for treatment decision making, as more therapeutic targets emerge and genetic information enters the classification of brain tumors.Keywords
This publication has 29 references indexed in Scilit:
- Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid TumorsNeoplasia, 2015
- A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panelExperimental and Molecular Pathology, 2015
- Sequence Artifacts in DNA from Formalin-Fixed Tissues: Causes and Strategies for MinimizationClinical Chemistry, 2014
- Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened InhibitionCancer Cell, 2014
- Reducing Sequence Artifacts in Amplicon-Based Massively Parallel Sequencing of Formalin-Fixed Paraffin-Embedded DNA by Enzymatic Depletion of Uracil-Containing TemplatesClinical Chemistry, 2013
- Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytomaNature Genetics, 2013
- Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibodyActa Neuropathologica, 2011
- TEQC: an R package for quality control in target capture experimentsBioinformatics, 2011
- EGFRvIII‐Targeted Vaccination Therapy of Malignant GliomaBrain Pathology, 2009
- Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytomaActa Neuropathologica, 2009